Advertisement

Topics

DBV shares jump as peanut allergy patch heads to filing

01:19 EST 15 Feb 2018 | BioPharmaDive

Eight years on from its first U.S. clinical trial, DBV Technologies' immunotherapy patch to combat peanut allergy could be submitted for U.S. approval in the second half of 2018.

Original Article: DBV shares jump as peanut allergy patch heads to filing

NEXT ARTICLE

More From BioPortfolio on "DBV shares jump as peanut allergy patch heads to filing"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...